Serum Institute Ready With 50M Covishield Doses
Updated On Dec 29, 2020
The Serum Institute of India, a prominent Covid-19 vaccine candidate has claimed to be ready with around 50 million doses of the coronavirus disease vaccine. It is to be noted that the Serum Institute is manufacturing the Indian version of Oxford-AstraZeneca coronavirus vaccine.
Adar Poonawalla, CEO, Serum Institute confirmed, "Our company has already manufactured 40-50 million doses of the novel coronavirus vaccine. In the initial phase, the rollout of the vaccine may be a bit slow, owing to logistics issues. However, we expected the roll out to be quick once things are sorted.” He further stated that the company will be able to increase the capacity to around 100 million by March 2021.
As per the reports of the Press Trust of India, the world-renowned Pune-based company has applied for emergency use authorization for Covishield, its Indian version of COVID-19 vaccine in the country to the Drugs Controller General of India. Adar Poonawalla stated that the Oxford-AstraZeneca vaccine could be approved in the UK anytime soon. Moreover, by the next month, the vaccine can also gain approval in India.
The news has emerged when about two million people in the United States have received the first of two coronavirus vaccine shots. According to the reports of the Centers for Disease Control and Prevention (CDC), 2,127,143 people in the US have received the first shot of the coronavirus vaccine while the distribution of 11,445,175 doses throughout the US has been carried out.
You May Like To Read:
Disclaimer: This article is issued in the general public interest and meant for general information purposes only. Readers are advised not to rely on the contents of the article as conclusive in nature and should research further or consult an expert in this regard.